Skip to main content

Operating profitability achieved, with a 794% increase in revenues from product sales, demonstrating the benefits of reacquiring RUCONEST® commercialisation rights in the US.

“The first quarter was very active for Pharming and importantly, it was the first full quarter in which we received all of the benefits of the acquisition of commercialization rights for RUCONEST® in North America from certain subsidiaries.''

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline